bufuralol has been researched along with metoprolol in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (35.00) | 18.7374 |
| 1990's | 2 (10.00) | 18.2507 |
| 2000's | 5 (25.00) | 29.6817 |
| 2010's | 6 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carrupt, PA; el Tayar, N; Testa, B; Van de Waterbeemd, H | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Caradonna, NP; Hallifax, D; Houston, JB; Turlizzi, E; Zanelli, U | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Burkart, F; Pfisterer, M; Steinmann, E | 1 |
| Lennard, MS | 1 |
| Smith, RL | 1 |
| Catin, T; Dayer, P; Gut, J; Kronbach, T; Meier, UT; Meyer, UA; Skoda, C | 1 |
| Lennard, MS; Ramsay, LE; Silas, JH; Tucker, GT; Woods, HF | 1 |
| Mautz, DS; Nelson, WL; Shen, DD | 1 |
| Blake, JA; Burchell, B; Friedberg, T; Gilham, DE; Glancey, MJ; Pritchard, MP; Wolf, CR | 1 |
| Cai, H; Guengerich, FP; Hanna, IH; Kim, MS; Krauser, JA | 1 |
| Ayrton, AD; Chenery, R; Clarke, SE; Deeni, YY; Paine, MJ; Wolf, CR | 1 |
| Hagihira, Y; Inoue, T; Murayama, N; Sasaki, E; Shimizu, M; Uehara, S; Uno, Y; Yamazaki, H | 1 |
2 review(s) available for bufuralol and metoprolol
| Article | Year |
|---|---|
Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Models, Molecular; Receptors, Adrenergic, beta; Structure-Activity Relationship | 1988 |
Oxidation phenotype and the metabolism and action of beta-blockers.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Animals; Drug Interactions; Ethanolamines; Humans; Hypertension; Kinetics; Metoprolol; Oxidation-Reduction; Phenotype; Propranolol; Timolol | 1985 |
18 other study(ies) available for bufuralol and metoprolol
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
Topics: Cell Line, Tumor; Cryopreservation; Female; Hepatocytes; Humans; Male; Metabolic Clearance Rate; Pharmaceutical Preparations; Predictive Value of Tests | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
Effects of bisoprolol in relation to metoprolol and bufuralol on left ventricular hemodynamics at rest and during exercise in chronic ischemic heart disease.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Coronary Circulation; Coronary Disease; Ethanolamines; Heart; Heart Ventricles; Hemodynamics; Humans; Metoprolol; Middle Aged; Physical Exertion; Propanolamines; Rest; Time Factors | 1986 |
Polymorphic metabolism of the beta-adrenoreceptor blocking drugs and its clinical relevance.
Topics: Adrenergic beta-Antagonists; Animals; Biological Availability; Blood Pressure; Debrisoquin; Ethanolamines; Glucuronates; Humans; Hydroxylation; Kinetics; Lipids; Metoprolol; Phenotype; Polymorphism, Genetic; Propranolol; Solubility; Structure-Activity Relationship; Timolol | 1985 |
The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.
Topics: Adrenergic beta-Antagonists; Cytochrome P-450 Enzyme System; Ethanolamines; Genetic Variation; Humans; Hydantoins; Hydroxylation; Isoenzymes; Kinetics; Mephenytoin; Metoprolol; Microsomes, Liver; Oxidation-Reduction; Polymorphism, Genetic; Structure-Activity Relationship; Tissue Donors | 1986 |
Oxidation phenotype and beta-blockers.
Topics: Adrenergic beta-Antagonists; Debrisoquin; Ethanolamines; Humans; Metoprolol; Oxidation-Reduction; Phenotype | 1983 |
Polymorphic metabolism of beta-adrenoceptor antagonists.
Topics: Adrenergic beta-Antagonists; Biotransformation; Drug Interactions; Ethanolamines; Heart Rate; Humans; Metoprolol; Propranolol | 1984 |
Regioselective and stereoselective oxidation of metoprolol and bufuralol catalyzed by microsomes containing cDNA-expressed human P4502D6.
Topics: Adrenergic beta-Antagonists; Biotransformation; Catalysis; Cells, Cultured; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Dealkylation; DNA; Ethanolamines; Humans; In Vitro Techniques; Kinetics; Metoprolol; Microsomes, Liver; Mixed Function Oxygenases; Oxidation-Reduction; Spectrometry, Fluorescence; Stereoisomerism; Verapamil | 1995 |
Functional co-expression of CYP2D6 and human NADPH-cytochrome P450 reductase in Escherichia coli.
Topics: Adrenergic beta-Antagonists; Base Sequence; Cytochrome P-450 CYP2D6; DNA Primers; Escherichia coli; Ethanolamines; Gene Expression; Humans; In Vitro Techniques; Kinetics; Metoprolol; NADPH-Ferrihemoprotein Reductase; Plasmids; Polymorphism, Genetic; Recombinant Proteins | 1998 |
Diversity in mechanisms of substrate oxidation by cytochrome P450 2D6. Lack of an allosteric role of NADPH-cytochrome P450 reductase in catalytic regioselectivity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Allosteric Regulation; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dopamine Agents; Ethanolamines; Metoprolol; Mixed Function Oxygenases; Models, Chemical; Molecular Conformation; NADPH-Ferrihemoprotein Reductase; Oxidation-Reduction | 2001 |
Expression, purification, and biochemical characterization of a human cytochrome P450 CYP2D6-NADPH cytochrome P450 reductase fusion protein.
Topics: Cytochrome P-450 CYP2D6; Dextromethorphan; Escherichia coli; Ethanolamines; Humans; Metoprolol; NADPH-Ferrihemoprotein Reductase; Pharmaceutical Preparations; Protein Engineering; Recombinant Fusion Proteins; Technology, Pharmaceutical | 2001 |
Marmoset cytochrome P450 2D8 in livers and small intestines metabolizes typical human P450 2D6 substrates, metoprolol, bufuralol and dextromethorphan.
Topics: Amino Acid Sequence; Animals; Callithrix; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Dextromethorphan; DNA, Complementary; Ethanolamines; Exons; Gene Expression Regulation, Enzymologic; Humans; Intestine, Small; Introns; Isoenzymes; Kinetics; Liver; Metoprolol; Molecular Sequence Data; Multigene Family; Organ Specificity; Oxidation-Reduction; Phylogeny; Recombinant Proteins; RNA, Messenger; Sequence Alignment; Sequence Analysis, DNA; Sequence Homology, Amino Acid | 2015 |